hotspot -WSS

hotspot

author：leisure time 2025-10-02 11:08:28 - browse：881

Primary care exam 01 — ReCor Medical, a startup owned by Japanese company Otsuka Medical Devices, and Medtronic have run studies that showed renal denervation leads to a modest decrease in blood pressure. Adam Berry/Getty Images

The Food and Drug Administration approved a surgical system used to reduce blood pressure from Recor Medical, the company announced Wednesday. The treatment, called renal denervation, is controversial in the cardiology community due to its unclear efficacy.

Renal denervation is a treatment for patients who cannot manage standard doses of blood pressure medication — whether because the drugs aren’t effective enough for them, create overwhelming side effects, or become too cumbersome. The therapy, which is meant to be a one-time procedure, is administered via a catheter. Electrodes on the catheter then emit radiofrequency or ultrasound energy to block nerve signals from the kidneys that increase blood pressure.

The therapy, a simple procedure to reduce the blood pressure of millions of Americans, was once seen as a boon for cardiologists and device makers. But a large-scale clinical trial from Medtronic in 2014 called renal denervation’s efficacy into question, as it did not significantly reduce blood pressure compared to placebo treatments.

Get unlimited access to award-winning journalism and exclusive events.

Subscribe Log In

Previous article： Cancer drug shortages should be causing more outrage
Next article： Chemotherapy drug shortage eases slightly but still widespread

focus

WSS

Liquid biopsy for lung cancer is launched by Delfi

Bill would stop addiction treatment from triggering child abuse inquiry

FDA panel signals lack of confidence in Amgen cancer drug data

Why getting cancer drugs just got harder for rural patients

Pfizer highlights cancer drugs it thinks could reignite investor interest

Colorectal cancer study finds potential in overlooked immune cell

knowledge

hotspot

focus

New air purifier tech could be key to improving indoor air quality

Why age limits for politicians are a terrible idea

United colonoscopy coverage change 'may cost lives,' doctors say

Why getting cancer drugs just got harder for rural patients

United colonoscopy coverage change 'may cost lives,' doctors say

Colorectal cancer study finds potential in overlooked immune cell

Medicare proposal to cover medical devices draws a mixed reaction

AstraZeneca loses challenge to Medicare drug price negotiation

Cancer drug shortages should be causing more outrage

3 questions for the future of Biden's cancer moonshot

leisure time

FDA panel signals lack of confidence in Amgen cancer drug data

Readout LOUD Podcast: Legal insider trading, booming biotech stocks

Clinical trials giant ICON acquires HumanFirst

Change Healthcare cyberattack outage could last weeks

Bristol 'take

How to address the problem of discarded donor organs

explore

focus

hotspot

knowledge